GeneOne Life Science and Inovio Pharmaceuticals’ MERS Vaccine Approved for First-in-Human Study

Press Releases |

SEOUL, South Korea, Nov. 19, 2015 -- GeneOne Life Science Inc. (KSE:011000) today announced that the U.S. Food and Drug Administration has cleared the first-in-human clinical study of its collaborative vaccine for MERS (Middle East Respiratory Syndrome). GeneOne Life Science and Inovio Pharmaceuticals (INO) are co-developing the vaccine and plan to initiate the first human trial of a MERS vaccine before the end of the year in partnership with the Walter Reed Army Institute of Research (WRAIR).

Earlier this month, GeneOne Life Science signed a joint clinical development agreement with WRAIR to advance the MERS vaccine. As part of this agreement, the relevant MERS vaccine clinical trial will be conducted at Walter Reed Army Institute of Research.

Middle East Respiratory Syndrome is caused by a coronavirus that is related to the severe acute respiratory syndrome (SARS) virus that over 10 years ago infected more than 8,000 people, with a 10% death rate. There is no vaccine or effective treatment against MERS, which spreads from human to human. Since 2012, MERS has infected over 1,500 people and killed almost 600 (40%). Recently, the largest outbreak outside of Saudi Arabia of this emergent global health concern infected 186 people with 36 fatalities in South Korea.

Mr. Young K. Park, CEO, GeneOne Life Science, said, “We are moving rapidly with our partners to bring a MERS vaccine to medicine because there is no vaccine or treatment for this virulent virus that has triggered widespread outbreaks and deaths in the Middle East and more recently Korea.

About GeneOne Life Science

GeneOne Life Science Inc. is an international DNA vaccine developer and leading contract manufacturer of DNA plasmid-based agents for pre-clinical and clinical trials for global companies and institutions. It researches and develops DNA vaccines to prevent and treat incurable diseases in South Korea and internationally. The company is headquartered in Seoul, South Korea. VGXI, Inc., GeneOne's wholly-owned manufacturing subsidiary located in Texas, is the largest pure-play cGMP DNA plasmid manufacturing facility in the world.

GeneOne Life Science 
Jeffrey C. Richardson 


DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Symbol Name Price Change % Volume
INO Inovio Pharmaceuticals Inc. 6.41 -0.39 -5.74 1,640,366


Emerging Growth

Beleave Inc.

Beleave Inc is a biotech company. The Company is engaged in the production of medical marijuana under the Marihuana for Medical Purposes Regulations outlined by Health Canada.

Private Markets


Wealthfront is an automated investment service that serves as an alternative to traditional financial advisory services. The company manages a diversified, continually rebalanced portfolio of index funds on their clients’…


Cloudera offers enterprises a new data platform built on the Apache Hadoop open-source software package. Hadoop is a data-management platform that can consolidate data in a single repository for comprehensive…